RECITALSConditional Loan Conversion Agreement • November 26th, 2007 • China Biopharmaceuticals Holdings Inc • Pharmaceutical preparations • Delaware
ContractConditional Loan Conversion Agreement • May 5th, 2020 • Delaware
<DOCUMENT> <TYPE>EX-10.1 <SEQUENCE>5 <FILENAME>cbi_8k-ex10x1.txt <DESCRIPTION>EXHIBIT 10.1 <TEXT> Exhibit 10.1 Execution Version CONDITIONAL LOAN CONVERSION AGREEMENT THIS CONDITIONAL LOAN CONVERSION AGREEMENT (this "Agreement") is entered into as of November 16, 2007 by and between China Biopharmaceuticals Holdings Inc. ("CBH"), and RimAsia Capital Partners, L.P. ("RimAsia"). CBH and RimAsia hereinafter collectively may be referred to as the "Parties" and each individually as a "Party." RECITALS WHEREAS, in connection with the prior acquisition of Shenyang Enshi Pharmaceutical Co., Ltd. ("Enshi") by RACP Pharmaceutical Holdings Ltd. ("RACP"), which was set up by RimAsia for the sole purpose to acquire Enshi, RimAsia extended a loan in the aggregate principal amount of US$11.5 million to RACP (the "Loan") for the purpose of the acquisition of Enshi, pursuant to the terms and conditions of that certain Facility Agreement dated May 29, 2006 (the "Loan Agreement"). WHEREAS, CBH acquired R
